Perspectives on early communication of drug risks to the public.
Seligman
P J
PJ
Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. paul.seligman@fda.hhs.gov
Osborne
S F
SF
D016907:Adverse Drug Reaction Reporting Systems / Q000639:trends*; D003142:Communication; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D010353:Patient Education as Topic / Q000379:methods / Q000639:trends; D011634:Public Health / Q000379:methods / Q000639:trends*; D012307:Risk Factors